Phase 2 proof of concept study to treat the pain associated with irritable bowel syndrome with IMC-1
Latest Information Update: 26 Nov 2021
At a glance
- Drugs Celecoxib/famciclovir (Primary)
- Indications Pain
- Focus Proof of concept; Therapeutic Use
- Sponsors Virios Therapeutics
- 11 Nov 2021 According to a Virios Therapeutics media release, company filed IND with FDA to explore the utility of IMC-1 in treating patients diagnosed with IBS.
- 08 Feb 2021 New trial record
- 01 Feb 2021 According to a Virios Therapeutics, Inc media release, it is entering a collaboration with Dr. Michael Camilleri of the Mayo Clinic to explore the role of antiviral therapy in managing Irritable Bowel Syndrome (IBS). The first step in the collaboration is focused on designing a phase 2 proof of concept study to treat the pain associated with IBS, with the longer-term goal of conducting the phase 2 study.